30 closest matches · ranked by relevance
Anti-Hepatitis A Antibody Levels in Heathy Subjects
Primary: Percentage of Subjects Maintaining Protective Anti- HAV Antibody Levels — 26 Participants
Autoimmune Rheumatologic Disease
Primary: Hepatitis A Antibodies Titre — 9.4; 9.0; 394.7; 810.6 IU/L
Hepatitis A
Primary: Seroprotection at Month 1 — 95.9; 96.6 percentage of participants
Hepatitis A
Primary: Anti-hepatitis A Virus (Anti-HAV) Antibody Concentration — 748.1; 378.6; 419.3; 342.2 mIU/mL
Hepatitis A
Primary: Anti-hepatitis A Virus (Anti-HAV) Antibody Concentration — 593.6; 297.4; 363.2; 287.7 mIU/mL
Hepatitis A · Measles · Mumps
Primary: Participants With 1 or More Serious Vaccine-Related Adverse Experiences — 0; 1 participants
Hepatitis C
Primary: Point Prevalence of Hepatitis C Infection — 9 percentage of total subjects
Hepatitis B · Hepatitis A
Primary: Anti-hepatitis A (HAV) Antibody Concentrations — 1122.2; 1377.8; 998.6; 1347.1 mIU/mL
Hepatitis E · Immunisation
Primary: Number of Participants With Solicited Local Reactogenicity Events — 11; 3; 17; 1 Participants
Chronic Hepatitis B
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 5; 4; 5; 4 Participants
Hepatitis C · Human Immunodeficiency Virus · HIV Infections
Primary: Sustained Virologic Response (SVR) — 62 percentage of participants
Hepatitis C Virus (HCV)
Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in the Intention-to-Treat (ITT) Population — 96.2 percentage of…
Hepatitis B · Hepatitis A
Primary: Number of Subjects With Anti-hepatitis A Virus (HAV) Antibody Concentrations Above the Cut-off Value — 113; 100; 105; 92 subjects
Hepatitis A
Primary: Anti-hepatitis A Virus (HAV) Antibody Concentrations in HAV and HAV+MMR+V Groups. — 1390.4; 1895.2 mIU/mL
Hepatitis A Vaccine
Primary: Number of Subjects With Anti-hepatitis A Virus (HAV) Seropositivity Status at Approximately 8 Years Following Last Administered Havrix Dose — 223; 293; 77; 7 Participants
Chronic Hepatitis C Infection
Primary: Change in HCV RNA Viral Load — .24; .08 log(IU/mL) — p=0.05
Norovirus Infection
Primary: Frequency of Norovirus Gastroenteritis (NVG) — 5; 4 Participants
Chronic Hepatitis C Infection
Primary: Effect of HSV-2 Suppression on HCV Viral Load. — .18; .03 log(IU/mL)
Hepatitis A Virus
Primary: Antibody Response to Hepatitis A - Participants With a Serological Response — 182; 158 Participants — p=<0.001
Hepatitis B · Hepatitis A
Primary: Number of Subjects With Anti-hepatitis A (Anti-HAV) Antibody Concentrations Equal to or Above Cut-off Value — 25; 28; 23; 24 Participants
Chronic Hepatitis B
Primary: Incidence of Adverse Events (AEs) — 4; 3; 4; 5 Participants
Hepatitis A · Hepatitis B
Primary: Number of Subjects Seropositive for Anti-hepatitis A Virus Antibodies (Anti-HAV) and Anti-hepatitis B Surface Antigen (Anti-HBs) Antibodies and With Anti-HBs Antibody…
Breast Cancer · Hepatitis C
Primary: Prevalence of HCV Seropositivity in Breast Cancer Patients. — 88; 15; 317; 130 Participants — p=0.0027
Hepatitis C
Primary: Number of Participants With Chronic Hepatitis C Virus (HCV) Infection at 6 Months — 14; 14 Participants — p=0.317
Hepatitis B · Hepatitis A
Primary: Anti-hepatitis A Virus (Anti-HAV) Antibody Concentration — 692.3; 753.6; 544.4; 479.5 milli-international units per milliliter
Hepatitis B · Hepatitis A
Primary: Anti-hepatitis A Virus (Anti-HAV) Antibody Concentration — 369.1; 323.5; 293.7; 298.2 mIU/mL
Hepatitis C
Primary: Intrahepatic and Plasma HCV Viral Kinetics — 6.5; 4.9; 3.2; 4.2 log transformed copies/ml
HIV-1 Infection · Hepatitis
Primary: Percentage of Participants With Sustained Virologic Response 12 (SVR12) — 58.8; 100.0 Percentage of participants
Hepatitis C
Primary: Attributes of Treatment Experience — 14; 15; 7; 9 participants
Healthy Volunteers
Primary: Percentage of Participants HAV/Dengue Virus (DENV)-Naive at Baseline Who Are Seroprotected Against HAV at Day 30 — 97.1; 9.1; 98.7 percentage of participants